ANI Pharmaceuticals Inc (NASDAQ:ANIP) SVP Robert W. Schrepfer sold 4,651 shares of the company’s stock in a transaction dated Wednesday, March 13th. The stock was sold at an average price of $64.43, for a total transaction of $299,663.93. Following the transaction, the senior vice president now owns 53,484 shares of the company’s stock, valued at approximately $3,445,974.12. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
Shares of ANI Pharmaceuticals stock traded down $0.25 during mid-day trading on Friday, hitting $63.49. The stock had a trading volume of 54,491 shares, compared to its average volume of 70,456. ANI Pharmaceuticals Inc has a 12-month low of $36.92 and a 12-month high of $72.81. The company has a debt-to-equity ratio of 0.34, a current ratio of 0.92 and a quick ratio of 0.68. The stock has a market cap of $755.38 million, a price-to-earnings ratio of 13.77 and a beta of 2.41.
ANI Pharmaceuticals (NASDAQ:ANIP) last posted its quarterly earnings results on Wednesday, February 27th. The specialty pharmaceutical company reported $1.32 earnings per share for the quarter, beating the consensus estimate of $1.24 by $0.08. ANI Pharmaceuticals had a net margin of 7.69% and a return on equity of 28.84%. The business had revenue of $57.12 million during the quarter, compared to analysts’ expectations of $53.48 million. During the same quarter in the prior year, the company posted $1.08 EPS. The business’s revenue for the quarter was up 20.8% on a year-over-year basis. Equities analysts expect that ANI Pharmaceuticals Inc will post 5.74 earnings per share for the current fiscal year.
Several research analysts recently weighed in on the stock. ValuEngine upgraded shares of ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday, February 4th. BidaskClub upgraded shares of ANI Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, November 22nd. Cantor Fitzgerald set a $74.00 price target on shares of ANI Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, December 28th. Finally, Raymond James set a $73.00 price target on shares of ANI Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, February 28th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. ANI Pharmaceuticals currently has a consensus rating of “Buy” and a consensus target price of $71.50.
TRADEMARK VIOLATION NOTICE: “ANI Pharmaceuticals Inc (ANIP) SVP Robert W. Schrepfer Sells 4,651 Shares of Stock” was originally posted by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this article on another publication, it was illegally stolen and republished in violation of United States and international copyright and trademark legislation. The correct version of this article can be read at https://sportsperspectives.com/2019/03/15/ani-pharmaceuticals-inc-anip-svp-robert-w-schrepfer-sells-4651-shares-of-stock.html.
ANI Pharmaceuticals Company Profile
ANI Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States. It focuses on producing controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations. The company offers Erythromycin Ethylsuccinate to treat infections; Esterified Estrogen with Methyltestosterone for treating vasomotor symptoms of menopause; Etodolac to treat pain caused by osteoarthritis, rheumatoid arthritis, and other conditions; Fenofibrate for treating hypercholesterolemia; Flecainide to treat arrhythmia; Fluvoxamine for treating obsessive-compulsive and social anxiety disorders; and hydrocortisone enema and cortenema to treat ulcerative colitis.
Featured Story: Options Trading
Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.